Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 2 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $55.0, with a high estimate of $70.00 and a low estimate of $39.00. Observing a downward trend, the current average is 9.41% lower than the prior average price target of $60.71.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Ionis Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joshua Smith | Redburn Atlantic | Announces | Neutral | $39.00 | - |
| Jessica Fye | JP Morgan | Lowers | Neutral | $45.00 | $47.00 |
| Jessica Fye | JP Morgan | Lowers | Neutral | $47.00 | $51.00 |
| David Lebowitz | Citigroup | Lowers | Buy | $64.00 | $67.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $70.00 | $70.00 |
| Kostas Biliouris | BMO Capital | Lowers | Market Perform | $45.00 | $60.00 |
| Joseph Stringer | Needham | Maintains | Buy | $60.00 | $60.00 |
| Luca Issi | RBC Capital | Maintains | Outperform | $70.00 | $70.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ionis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Ionis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Ionis Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Ionis Pharmaceuticals analyst ratings.
Discovering Ionis Pharmaceuticals: A Closer Look
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Financial Milestones: Ionis Pharmaceuticals's Journey
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Ionis Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -30.18%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -46.05%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE excels beyond industry benchmarks, reaching -16.68%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -3.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.41, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for IONS
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2025 | Redburn Atlantic | Initiates Coverage On | Neutral | |
| Mar 2025 | JP Morgan | Maintains | Neutral | Neutral |
| Mar 2025 | JP Morgan | Maintains | Neutral | Neutral |
View More Analyst Ratings for IONS
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
